CURE® TV

With CURE TV®, you have access to a variety of informative and uplifting videos. You’ll find interviews with cancer experts, advocates, patients, caregivers, as well as highlights from our celebratory events showcasing interviews with award winners and celebrity speakers.

Circulating Tumor DNA May Have Prognostic Value in Kidney Cancer

February 4th 2025, 10:00pm

Video

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.

Rybrevant Alone and in Combo With Chemo is Efficacious in Wildtype+ mCRC

February 3rd 2025, 8:00pm

Article

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.

Cabometyx Demonstrates PFS Benefit Versus Placebo in GI-NETs

February 3rd 2025, 2:00pm

Video

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs.

A Cancer Institution is Seeking to Address Food Insecurity in Patients With Cancer

January 29th 2025, 4:00pm

Video

Dr. Anna Arthur discusses the NOURISH trial, which aims to address food insecurity and malnutrition in patients with blood cancers undergoing treatment.

An Expert Shares Her Advice For Managing Side Effects in Cervical Cancer

January 28th 2025, 2:00pm

Video

Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cervical cancer who are experiencing side effects.

How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care

January 27th 2025, 2:00pm

Article

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.

The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC

January 26th 2025, 3:00pm

Video

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.

Afinitor Plus Somatuline May Improve Survival in Aggressive GEP-NETs

January 25th 2025, 7:36pm

Video

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.

An Expert Expands on What Drives ‘Exceptional’ Responses to RCC Treatment

January 22nd 2025, 3:00pm

Video

Dr. David A Braun delved into detail on the molecular factors driving exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Understanding the Challenges of CAR T-Cell Therapy Treatment in R/R NHL

January 22nd 2025, 2:00pm

Video

Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma.